SOST and osteogenesis imperfecta: Given the positive outcome attained with setrusumab (an anti-sclerostin antibody) in adults with OI holding promise and progression to phase 3 studies in this condition [64], the value of a combination therapy holds potential for further clinical benefit in OI patients where sclerostin is another protein target associated with the Wnt signaling pathway.